Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06351345
PHASE2
129 Xenon Imaging in Patients Treated With Sotatercept
Sponsor: Bastiaan Driehuys
View on ClinicalTrials.gov
Summary
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
Official title: 129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2025-10-27
Completion Date
2030-02-04
Last Updated
2026-02-24
Healthy Volunteers
No
Interventions
DRUG
129Xe Hyperpolarized
Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
Locations (1)
Duke University Medical Center
Durham, North Carolina, United States